Who fits the FDA-approved sleep-apnea indication?
The labeled population is adults with obesity and moderate to severe obstructive sleep apnea.
The diagnosis and severity should be established through a qualified evaluation. The label does not extend the sleep-apnea indication to children, people with mild sleep apnea, people without obesity, or other GLP-1 products. A clinician still needs to review medical history, current medicines, contraindications, and treatment goals.
What did the Zepbound sleep-apnea studies measure?
Two randomized, placebo-controlled trials followed 469 adults for 52 weeks and measured change in the apnea-hypopnea index, or AHI.
One trial enrolled people who were unable or unwilling to use positive airway pressure (PAP); the other enrolled people who were using PAP. Participants had obesity and moderate to severe obstructive sleep apnea, and people with type 2 diabetes were excluded. The FDA concluded that Zepbound reduced breathing events compared with placebo, but an average trial result cannot predict one person's response.
Can Zepbound replace CPAP?
Zepbound and PAP should not be treated as interchangeable, and PAP should not be stopped without clinical reassessment.
PAP can support the airway during sleep when it is used, while medication response and weight change develop over time. Feeling better or snoring less does not prove that breathing events have normalized. The clinician managing sleep apnea may use symptoms, PAP data, examination, and repeat sleep testing before changing treatment.
What safety questions belong in the conversation?
Use the current prescribing information—not a class-wide summary—to review whether Zepbound is appropriate.
The current label includes a boxed warning about thyroid C-cell tumors and contraindicates use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It also describes important risks and precautions involving severe gastrointestinal reactions, kidney injury from volume depletion, gallbladder disease, pancreatitis, serious hypersensitivity, low blood sugar with certain diabetes medicines, diabetic retinopathy complications, and pulmonary aspiration during general anesthesia or deep sedation. Tell the prescribing and procedural teams about all medicines and planned procedures.
Will insurance or Medicare cover Zepbound for sleep apnea?
Coverage is plan-specific; FDA approval does not guarantee payment.
Ask the drug plan whether Zepbound is on its formulary for moderate to severe obstructive sleep apnea, whether prior authorization is required, and what diagnostic documentation is needed. Medicare's current GLP-1 information says people with moderate to severe sleep apnea may have coverage through their Part D plan rather than the separate GLP-1 Bridge program. Confirm the current rule directly with the plan before treatment or renewal.
Appointment checklist
Bring four answers to the prescribing visit
A useful appointment connects the medication decision to the existing sleep-apnea plan.
- 1
Diagnosis and severity
Bring the sleep-study result, including the AHI and date, plus the clinician's diagnosis.
- 2
Current sleep treatment
List PAP settings and use, oral-appliance use, prior procedures, current symptoms, and any problems tolerating treatment.
- 3
Medication and safety history
Bring all prescriptions, over-the-counter medicines, supplements, allergies, relevant family history, and planned procedures involving anesthesia or deep sedation.
- 4
Monitoring and coverage plan
Ask who will monitor side effects, weight, daytime function, sleep-apnea response, refills, prior authorization, and the timing of reassessment.
Common questions
Questions patients ask first
Which GLP-1 is FDA approved for sleep apnea?
Zepbound (tirzepatide), a GIP and GLP-1 receptor agonist, has an FDA-labeled indication to treat moderate to severe obstructive sleep apnea in adults with obesity, together with a reduced-calorie diet and increased physical activity.
Are Ozempic or Wegovy approved to treat sleep apnea?
The FDA sleep-apnea approval described here is specific to Zepbound. Do not transfer that indication to another product; check the current FDA labeling for the exact medicine and indication.
Can I stop CPAP after starting Zepbound?
Do not stop PAP without the clinician managing your sleep apnea. Medication response, weight change, feeling better, or less snoring do not by themselves confirm that airway obstruction has resolved.
Does weight loss cure sleep apnea?
Weight reduction may improve obstructive sleep apnea when obesity contributes, but it does not guarantee resolution. Follow-up and sometimes repeat sleep testing are needed before changing treatment.
Does Medicare cover Zepbound for sleep apnea?
Coverage depends on the specific Part D plan and its requirements. Medicare's current GLP-1 information says people with moderate to severe sleep apnea may have Part D coverage rather than qualifying through the separate GLP-1 Bridge program. Check the plan formulary and prior-authorization rules directly.
What should I ask before a procedure or surgery?
Tell the prescribing clinician and the procedural or anesthesia team that you take Zepbound. The current label includes a warning about pulmonary aspiration during general anesthesia or deep sedation; the treating team should give individualized instructions.
Authoritative sources
Review the public guidance
- FDA: First Medication Approved for Obstructive Sleep Apnea
- DailyMed: Current ZEPBOUND Prescribing Information
- DailyMed: ZEPBOUND Medication Guide
- Medicare: Current GLP-1 Drug Coverage Information
- Medicare: Sleep Study Coverage
Domenico Savatta, MD reviewed this page for publication. Source links support education, not a personal recommendation.